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Purpose: Enhancing oral bioavailability of vinpocetine by forming its amorphous citrate salt through a solvent-free mechanochemical process, in presence of micronised crospovidone and citric acid.
Methods: The impact of formulation and process variables (amount of polymer and citric acid, and milling time) on vinpocetine solubilization kinetics from the coground was studied through an experimental design. The best performing samples were characterized by employing a multidisciplinary approach, involving Differential scanning calorimetry, X-ray diffraction, Raman imaging/spectroscopy, X-ray photoelectron spectroscopy, solid-state NMR spectroscopy, porosimetry and in vivo studies on rats to ascertain the salt formation, their solid state characteristics and oral bioavailability in comparison to vinpocetine citrate salt (Oxopocetine®). 
Results: The analyses attested that the mechanochemical process is a viable way to produce in absence of solvents vinpocetine citrate salt in an amorphous state. 
Conclusion: From the in vivo studies on rats the obtained salt resulted to be 4 times more bioavailable than its physical mixture and bioequivalent to the commercial salt produced by conventional synthetic process implying the use of solvent.  
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Introduction
Vinpocetine (VIN) is a vincamine derivative and presents a series of very interesting pharmacological properties in relation to cerebral circulation, acting on vascular resistance, particularly in the area of blood vessels (1). It has been  shown to improve cerebral circulation and metabolism in the management of various types of cerebrovascular circulatory disorders, e.g. cerebral infarction, cerebral hemorrhage residual and cerebral arteries cirrhosis (2) and for the treatment of cognitive disorders and related symptoms (3).  However, as a consequence of its low aqueous solubility and wettability, and extensive metabolism during first pass, VIN suffers from poor oral bioavailability (~6.7%) (4-5). Hence, faced with its various pharmacological  properties, its clinical use is greatly restricted. So there is a need to improve its poor aqueous solubility to increase its oral absorption.
With this purpose, several approaches have been attempted. The most common consisted in its complexation  in cyclodextrins, in some cases with the help of a ternary component (6-9), because VIN chemical structure allows at least a portion of the molecule to be housed inside the cavity of the cyclodextrins (9). Other experiences were intended to counteract its poor solubility and wettability by means of  hydrophilic carriers (2, 10) or to take advantage of its lipophilic character (its partition coefficient is ranging about 3 (11)) by incorporation in self emulsifying systems (12-14). 
Recently, our group has successfully increased its oral absorption by cogrinding VIN with micronized crospovidone in a planetary mill using an optimized  mechanochemical activation process (15).  In that experience, the mechanical loading has caused particles’ comminuting and disordering of lattice structure, so that the solid has gained an activated state more prone to dissolution (e.g. by forming nanocrystalline or amorphous phases).
In the present research, with the aim of facilitating VIN oral absorption, the formation of the VIN water-soluble citrate was investigated. The transformation of the parent drug in the salt form permits rapid absorption and unaltered or even increased pharmacological actions (16). If the chemical approach is classical, the procedure adopted to prepare the salt is original. In fact, in this experience VIN citrate was obtained by proton transfer through a solid state reaction conducted with the aid of the mechanical energy. To go into more details, VIN was subjected to a mechanochemical treatment in presence of citric acid as a reactant, and crosslinked polymer (micronized crospovidone) as a processing aid.  In this case the mechanical energy, and in particular the shearing forces resulting from the rolling of ball elements on the wall of the planetary mill bowl, were used for the dry synthesis of VIN citrate.  In fact, the so-called pharmaceutical “mechanocomposites” can be successfully prepared by mechanical treatment of mixtures of the solid reactants, with the advantage of  a more convenient, cheaper and environmentally friendly process (17). Thus, such an approach represents a solvent-free green technology in alternative to patented synthesis (16) involving the use of solvents.




VIN was a kind gift from Linnea SA (Riazzino-Locarno, CH). Oxopocetine® (vinpocetine citrate-VIN citrate) was kindly donated by Covex s.a. (Madrid, Spain). Citric acid was provided by Sigma-Aldrich (Milano, Italy). Micronized crospovidone (PVP-CL) was purchased from BASF (Ludwigshafen, Germany). All other analytical-grade chemicals and solvents of HPLC grade, were provided by Carlo Erba (Milan, Italy). 

Preparation of coground mixtures
Drug and citric acid were coground in different drug-to-citric acid weight ratios in presence of  crospovidone in several drug-to-polymer weight ratios according to the experimental plan (Table I) in a planetary mill Fritsch P5 (Pulverisette, Contardi Fritsch s.r.l., Milan, Italy). The planetary mill was equipped by 4 agate cylindrical grinding chambers (internal height Hv=2.6 cm, internal radius Rv=3.2 cm, internal volume = 27.5 cm3) adopting agate balls (diameter 2.2 cm) as grinding media.
Six gram batches, previously blend in the suitable proportions with a stainless steel spatula, were simultaneously coground. The following operative conditions were selected on the basis of a previously published ah hoc mathematical model (18): maximum velocity (10,000 rpm), bowl loading (6 g), number of grinding media (6 agate balls).
The grinding procedure was pursued for 3 milling times, according to the experimental plan below reported, stopping every 5 min for homogeneously mixing the mass with a stainless steel spatula. Three factors, 2 formulation variables (drug-to-citric acid wt ratio - X1 and drug to polymer wt ratio - X2), and a process variable (milling time - X3) were selected for investigation. Each factor was considered in different experimental levels, selected during preliminary trials: 2 levels for drug-to-citric acid weight ratio - X1 (1:1.1, 1:0.55 corresponding to 1:2 and 1:1 molar ratio, respectively), 3 levels for drug-to-polymer weight ratio - X2 (1:2, 1:4, 1:7) and 3 experimental levels for milling time - X3 (15, 30, 60 min). The effect of these variables on a coground characteristic (amount of VIN solubilized in 120 min - Y) was statistically evaluated. The experimental plan (shown in Table I) was designed using nemrodw program (19) and the statistical analysis was performed by standard R package (20). To reduce systematic errors, experiments were completely randomized. 
Preparation of physical mixtures
Physical mixtures (PM) were prepared in batches of 12 g,  by manually mixing drug, citric acid and polymer with a stainless steel spatula for the standardized time of 5 min. The component weight proportions were selected according to the experimental plan. Six grams were then used for cogrinding experiments (see previous paragraph) and the rest was for comparison purposes.
Differential scanning calorimetry (DSC)
Calorimetric analyses were conducted using a differential scanning calorimeter (Mod. TA 4000, equipped with a measuring cell DSC 20 Mettler) using the STARe software version 9.30. The calibration of the instrument was carried out with indium, zinc and lead for the temperature, and with indium for the measurement of the enthalpy. Samples, containing about 2 mg of VIN were placed in pierced aluminum pans and heated at a scanning rate of 10°C/min from 30 to 250°C, under static air. 
X-ray Powder Diffraction Studies (XRD)
XRD technique was employed to study the solid state of the samples using a D500 (Siemens, Munich, Germany) diffractometer with Cu-K radiation (1.5418 Å), monochromatized by a secondary flat graphite crystal. The current was 20 mA and the voltage 40 kV. The scanning angle ranged from 5 to 35° of 2, steps were of 0.05° of 2, and the counting time was of 5 sec/step.
Raman imaging/spectroscopy 
Raman spectra and images were acquired for coground composites, PM and pure components using an inVia Raman system (Renishaw plc, Wotton-under-Edge, UK), equipped with a 300 mW diode NIR laser emitting at 785 nm (Renishaw) and a ProScanTMII motorized stage (Prior, Cambridge, UK). The laser was focused on the sample (consisting of 300 mg tablets with flat surfaces, prepared from physical and coground mixtures having different drug-to-citric acid and drug-to-polymer weight ratios, and from pure components) by a 50X objective (0.75 N.A.). To ensure a better sampling for each tablet by taking into account local variations in composition, an area of 84x84 μm was mapped with a grid of 2.8 μm (corresponding to 900 spectra per map) for each sample, using the StreamlineTM fast imaging configuration and the WiRE 3.1 software (Renishaw), with an total collection time of 13 min/map. Raman maps were then pre-processed (cosmic rays removal and baseline correction) and analyzed with the HyperSpec software package (21) for R (20); an average spectrum was calculated for each map, and images depicting the intensity ratio between VIN 1610 cm-1 band and the PVP-CL 1668 cm-1 band were produced. 
X-ray Photoelectron Spectroscopy (XPS)
All XPS spectra were acquired at room temperature in normal emission geometry using a conventional Mg K X-ray source (hν=1253.6 eV) and a 120° hemispherical electron energy analyser (overall energy resolution: about 0.8 eV). The binding energy scale has been calibrated by fixing the C 1s photoemission line due to hydrocarbon to 284.6 eV. All spectra were normalized to the incident photon flux and were analysed by performing a non-linear mean square fit of the data following the Levenberg-Marquardt algorithm. A linear background was used and the total photoemission intensity was reproduced by using Gaussian profiles.
Solid-state Nuclear Magnetic Resonance (SS NMR) spectroscopy
15N SS NMR spectra were recorded on a Bruker Avance II 400 instrument operating at 400.23 and 40.55 MHz for 1H and 15N nuclei, respectively. Cylindrical 4 mm o.d. zirconia rotors with a sample volume of 120 μL were employed and spun at 7 kHz. A ramp cross-polarization pulse sequence was used with a contact time of 4 ms, a 1H 90° pulse of 3.05 μs, recycle delays of 3-15 s, and 15000-26000 transients. A two pulse phase modulation (TPPM) decoupling scheme was used with an rf field of 75 kHz. 15N chemical shifts were referenced with the resonance of (NH4)2SO4 (15N signal at δ=355.8 ppm with respect to CH3NO2).
Porosity measurements
The porosity of the samples has been determined by a mercury porosimeter (ThermoQuest) equipped by Macropore Pascal 140 low pressure porosimeter and Macropore Pascal 240 high pressure porosimeter (CE Instruments, Italy). A dilatometer for powders with capillary diameter of 1.5 mm was loaded with 300 mg samples. Before measuring, a degasification procedure under vacuum pressure for 30 min was performed. The experiments were performed in triplicate. The size distribution was calculated applying the Mayer and Stowe method (22).
Dissolution kinetics tests (DKT)
Release tests, performed in triplicate, were led in 150 cm3 of 0.2 M KH2P04/0.2 M NaOH (pH 7.4) at 37 ± 0.3°C. At this pH value the estimated solubility of pure VIN was 1.6 mg/l. At time zero, a suitable amount of sample (as a pure compound or ternary systems) to give 5 mg of active was added to the release environment. Uniformity conditions were ensured by using an impeller (rotational speed 200 rpm). The use of a fiber optic apparatus (HELLMA, Milano, Italy), connected to a spectrophotometer (ZEISS, Germany, wavelength 270.19 nm), permitted the determination of VIN concentration without perturbing the release environment (each release test lasted 120 min). Moreover, this methodology, previously successfully employed for coground systems containing VIN (15) allowed to easily overcome the problem connected to drug concentration measurements in presence of a dispersion of solid particles. Indeed, whilst the maximum VIN absorption occurred at 270.19 nm, the maximum citric acid absorption was at 220.49 nm and the scattering effect due to polymeric particles uniformly occurred at every wavelength. Accordingly, the real absorbance associated to VIN concentration was the difference between the absorbance measured at 270.19 nm and that measured at 500.49 nm (at 500.49 nm VIN did not absorb). Non-sink conditions were used in release environment. 
In vivo absorption studies
Procedures for rats care and management complied with those required by Italian laws (D.L.vo 116/92) and associated guidelines in the European Communities Council Directive of 24 November 1986 (86/609 ECC). Further, they adhered to ethical standards for humane treatment of experimental animals established by the ethical committee of University of Trieste. 
Sprague-Dawley rats (450 g weight) were supplied by Centro Servizi Polivalenti di Ateneo (University of Trieste). Rats, with free access to water, were fasted overnight. Each experimental formulation was administered to 4 rats by gastric gavage in the form of aqueous suspensions (2 ml corresponding to a dose 11 mg/kg of VIN). 
Blood samples (600 l) were then collected using the “cannulated” tail artery method (22) in heparinized tubes at 30, 60, 90, 120, 180 and 360 min after administration. Blood samples were added of 66l of a 40 mM tetrasodium EDTA solution, centrifuged at 166 g for 10 min and plasma was separated and immediately frozen at -80°C, and stored at this temperature till the analysis.
Assays of Vinpocetine in powder and plasma samples
HPLC analysis
For the determination of the drug content in the PM, coground systems and pure compounds the procedure was the following: a suitable amount of powdered sample was accurately weighed and transferred to a 100 ml volumetric flask and diluted with acetonitrile. The mixture was subjected to sonication for 10 min and then filtered through a syringe filter (RC 0.45 µm, Phenomenex, Castel Maggiore, Bologna) to remove any particle. The first 5 µl of the filtrates was discarded while the subsequent was collected. Then, an appropriate amount of the filtrate was diluted with acetonitrile and assayed by a validated high pressure liquid chromatographic (HPLC) with mass spectrometry (MS) detection method (24) already used in our previous work (15). 
As for the determination of VIN in plasma samples, the following procedure was adopted: 600 l methanol were added to 200 l plasma, and the resulting mixture was vortexed for 10 min. After centrifugation (1845 g for 6 min), 5 l of the solution was injected. The VIN determination was carried out using the aforementioned method.

Pharmacokinetic analysis
Pharmacokinetic parameters were calculated on the plasma curves. The area under the plasma concentration-time curve extrapolated to the last sampling time at which a quantifiable concentration is found (AUCt=6) was calculated using the log-linear trapezoidal method. Time and value of maximum concentration (tmax and Cmax, respectively) were reported as observed. The relative bioavailability of after oral administration (Frel) was calculated in Eq. 1: 
							(1)
Pharmacokinetic analysis was carry out using WinNonlin Version 5.2 (Pharsight Corporation, Mountain View , CA ) software. 
Aging studies
The best performing sample was kept at 25°C in a thermostated oven and subjected to DSC and XRD analyses every 9 months over a period of 18 months. 

results and discussion
The aim of the work was to enhance the solubility of VIN, and thereby improve its oral bioavailability, by means of water-soluble citrate salt formation. After the preparation, the best samples were extensively characterized in comparison to starting VIN to verify the in vitro dissolution enhancement, and in comparison to commercial VIN citrate salt, Oxopocetine®, to verify the physico-chemical correspondence and bioequivalence of our product. 
In particular, to prepare the salt as an alternative to patented procedure of VIN citrate involving the use of solvents (16), a solid state reaction conducted with the aid of the mechanical energy was used, employing micronized crospovidone as a processing aid and citric acid as a reactant. 
This hydroxyacid, commonly used in pharmaceutical preparations, is frequently employed as dissolution enhancer in ternary mixtures (25) and it has the property to form amorphous structures with poorly soluble drugs when processed in certain conditions (26). Further, it possesses  favorable physical properties for an use in solid-solid reactions, such as its glass transition in the dry state of 11°C (26). In fact, it must be born in mind that the plasticity of the reactants is a factor of primary importance in solid-solid reactions, since it influences the ease with which the contacts between the reactants are formed (17). 
Micronized crospovidone, whose compatibility with VIN has been previously demonstrated (15), in earlier mechanochemical experiences has shown its ability to reduce drug adhesion to the grinding media and to the walls of the mixing bowl (27). Moreover, the amorphous polymer network can act as a stabilizer towards the drug meta-stable activated status possibly resulting from high energy milling (17, 28). In addition, the presence of a certain amount of water in the polymer  (29) may decrease the fragility of the citric acid (26), favoring its solid reactivity. Finally, the polymer can positively contribute to the active dissolution performance by preventing one of the major concerns about pharmaceutical salts of poorly water-soluble weak bases, e.g. the precipitation of the salt at pH values found in the g.i. tract (30).  
The grinding process was conducted in optimized conditions using a Fritsch P5 planetary mill, that is particularly suitable for its lab scale for performing a study of screening among variables. In this apparatus the mechanocomposite is mainly obtained by the creation of shearing interactions, as a result of the rolling of ball elements on the wall of the grinding container. 
The grinding procedure was carried out using different sample compositions and 3 operating conditions according to the experimental plan reported in Table I. In particular, three factors, 2 formulation variables (drug-to-citric acid wt ratio - X1 and drug to polymer wt ratio - X2), and a process variable (milling time - X3) were selected for investigation. Each factor was considered in different experimental levels, selected during preliminary trials: 2 levels for drug-to-citric acid weight ratio (X1), 3 levels for drug-to-polymer weight ratio (X2) and 3 experimental levels for milling time (X3). The effect of these variables was statistically evaluated on the amount of solubilized drug after 120 min from the coground product (Y), in consideration of the aim of the research. To reduce systematic errors, the resulting 27 experiments were run randomly. 
An inspection of the boxplots (Fig. 1) suggested that a remarkable influence of the response was only obtained from the milling time variable (X3) where 30 min factor level showed a significant improvement of the output Y. 
However, for a better statistical evaluation so-called Tukey’s “Honest Significant Difference” (HSD) 95% method data was computed.  To compare the means of output Y (the amount of drug solubilized after 120 min), the levels of factors X1, X2 and X3  have been ordered according to increasing mean of Y, before taking differences, so that the calculated differences in the means are positive. The results are listed in Table II and represented in a graph-mode in Fig. 2. 
From these data, the influence of  VIN-citric acid weight ratio (X1) on the drug dissolution was not significant (p=0.948). 
Conversely, very interesting was the effect of the drug-to-polymer weight ratio (X2): the lower the amount of polymer used, the higher the amount of solubilized drug, probably because a large amount of polymer reduces the possibility of interaction between citric acid and VIN. The number of contacts between reacting particles is in fact of crucial importance for solid-solid reactions (17). It was emphasized that sometimes, for the rate of interaction, the formation of contacts is a limiting step more important than the rate of the chemical reaction itself. (17).
As for the time factor (X3), this was the most influencing parameter and 30 min is the optimal processing time. It appeared that an activation time of 15 min is not sufficient to achieve the maximum concentration of VIN in solution. On the contrary, the mechanical energy given in 60 min was excessive and induced a worsening of the performance. A first possibility is that milling is contributing to hydrophobicity because of air adsorption to the new formed surfaces. A further possible explanation of the deterioration of the solubilization performances with increased milling time can be an increased particle size of the coground system (from 30 to 60 min of milling time).  This hypothesis was verified by analyzing the particle size of a coground system (1:1.1:2 drug-to-citric acid-to-polymer wt ratio) after 30 and 60 min of milling process. In Fig. 3 the differential distribution as a function of the diameter in a log scale is depicted. Both samples showed a monomodal distribution, with a peak frequency value of 23.6 m in the case of 30 min coground (Fig. 3A), and of 44.9 m for 60 min coground (Fig. 3B). This data attested that continued milling time did not reduce particle size further; rather, the particle size raised remarkably. Probably crospovidone, necessary for avoiding adhesion phenomena to the grinding elements, was responsible for the undesired formation of agglomerates with the longest milling times, as in previous mechanochemical experiences (27, 31). Large agglomerates are undesired not only from the dissolution point of view but also in considerations of their influence on the development of the mechanically activated solid-state reaction. In fact, it is well known the importance of the correct adjustment of the size distribution of the particles in the reaction mixture in such a way as to provide the densest packing and prevent aggregation (32).
From the screening analysis it can be deduced that the best activation results are expected from the ternary systems containing a low amount of PVP-CL, processed for an intermediate time (30 min). As for citric acid content (X1), the dissolution performances of the systems having different drug to citric acid wt ratios resulted not significantly different and hence both ratios were selected for supplementary analyses. Therefore, the systems selected for further considerations were the following: 1:1.1:2 drug-to-citric acid- to-polymer wt ratio coground for 30 min and 1:0.55:2 drug-to-citric acid- to-polymer wt ratio for 30 min. For the sake of brevity, in the following these samples are named 1:1.1:2 and 1:0.55:2, respectively.
From Fig. 4 it can be noticed a great improvement of the solubilization kinetics, in terms of rate and extent of dissolved drug, in comparison to the pure VIN and the simple PM of the three components. To go into more details, in the DKT of the coground, the presence of a very rapid onset in the first 15 min of analysis followed by a pronounced supersaturation phenomenon was observed. An analogous initial burst phenomenon was noticed in the DKT of the commercial salt (also reported in Fig. 4).  In the second part of the dissolution process the coground was able to maintain higher levels of solubilized VIN, thanks to the presence of the polymer. This because the PVP-CL has the property of reducing in solution crystallization phenomena of poorly soluble drugs, as demonstrated by a recent study (33). 
In the subsequent step, the solid state characterization of the coground samples was performed in comparison to pure components, ternary PM and the reference salt, to study the influence of the mechanical treatment on the physical state of the drug. 
First, the ternary 1:1.1:2 and 1:0.55:2 coground systems were subjected to XRD analysis. In the pattern of PVP-CL (Fig. 5a) a complete lack of peaks and a halo pattern, typical of amorphous materials, were detected. Conversely, the crystalline drug showed intense reflections in the range between 10 and 25° of 2θ (Fig. 5b), in accordance to those previously reported for VIN by Ribeiro et al. (7) and Hasa et al. (15). The peaks of the citric acid (Fig. 5c) were detected in all  the range of analysis, but in particular those at 14.1, 18, 25.8, 28.8 and 32.3° of 2θ were worth of notice because they can permit an easy distinction from VIN in multicomponent mixtures. Ternary PM patterns (Fig. 5d and f) are simply the sum of the reflections of the drug and the citric acid, without any sign of interaction. In the 1:0.55:2 coground system (Fig. 5e), the diffractogram showed the presence of residual peaks attributable to both VIN and citric acid. This suggested only a partial amorphysation of components. The situation is completely different in the case of 1:1.1:2 coground system where a modest hump due to the attenuation of citric acid signals between 5 and 12° of 2 was visible, together with two peaks at 26.3 and 32.4° of 2 attributable to residual free (un-reacted) citric acid. Finally, Oxopocetine® appeared completely amorphous at the XRD analysis (Fig. 5h). Its baseline was dominated by two humps between 5 and 25° of 2, in correspondence to original VIN and citric acid signals, here attenuated. 
The physical characterization was pursued by means of DSC analysis. Pure VIN (Fig. 6b) exhibited a solid-liquid transition at 149.6°C, while citric acid presented an endothermal event at 156.7°C due to its melting, immediately followed by its degradation in air atmosphere (Fig. 6c). Crospovidone (Fig. 6a) in the considered temperature range lost its water between 30 and 120°C, starting its slow degradation at about 185°C. The DSC curve of the PM testified the absence of interactions among components (Fig. 6d and f). Conversely, in the 1:0.55:2 coground (Fig. 6e), according to previous XRD findings, a weak thermal event at about 145°C suggested the presence of nanocrystalline structures. For the 1:1.1:2 coground (Fig. 6g) no significant events of melting (attributable to the drug or to the citric acid) were visible; this means that neither of the two original crystalline components was still detectable in this sample. Differently from the previous XRD analyses, in the DSC curve of this coground no thermal event, attributable to the components, was detected. The commercial salt (Fig. 6h) did not show event of melting, but only a peak around 60°C and a moderate hump ranging about 170°C. The first thermal event is probably attributable to monohydrate citric acid, which according to literature shows in this range of temperatures its melting accompanied by the release of crystal water (34). As for the endothermal event at about 170°C, it is reported that citric acid when heated above 175°C is converted in decomposition substances by elimination of water and other components (35). 
Further information was gathered from Raman imaging/spectroscopy. Firstly, the effect of the co-grinding process on the spatial heterogeneity of the mixtures at microscopic level was evaluated. Comparison of Raman images of the 1:1.1:2 PM and coground (Fig 7 left and right respectively) revealed pronounced differences: an inhomogeneous distribution of VIN could be seen in the intensity Raman map of the PM (left), whereas a more homogeneous VIN distribution was observed in the Raman map of the 1:1.1:2 coground sample (right).
Raman spectra of PM (Fig. 8d and f) were a superimposition of the spectra of pure VIN and PVP-CL, whereas no bands due to citric acid (Fig. 8b) were detected. The absence of citric acid bands could be due to its smaller Raman cross section with respect to the other two components. In both PM spectra, frequencies and relative intensities of the bands due to VIN were unaffected with respect to the spectrum of pure VIN (Fig. 8c), indicating the absence of any interaction between VIN and the other components. This observation is in agreement with our recent Raman data on binary mixtures of VIN and PVP-CL (15). The situation was different in the case of the coground samples (Fig. 8e and g), whose Raman spectra cannot be reconstructed by a simple superposition of the pure components. In these spectra, the intense band due to an aromatic C=C stretching in VIN, which was found at 1610 cm-1 in spectra of pure VIN and in PM, was splitted into a doublet, with the second band, broader than the first, being at 1622 cm-1. The same changes occured for the C=O stretching band observed at 1716 cm-1 in pure VIN, which in the coground Raman spectra underwent a broadening and a shift to 1728 cm-1. Such spectral changes, which were significantly more pronounced in the 1:1.1:2 than in the 1:0.55:2 coground sample, were to be interpreted as an alteration of the VIN C=C and C=O enviroments in the coground samples with respect to the pure substance. Interestingly, similar spectral changes, although less pronounced, have been observed for binary coground mixtures of VIN and  PVP-CL (15), and can be interpreted as the disruption of the drug crystals. The larger band shift, with respect to pure VIN, observed in the 1:1.1:2 coground in comparison to 1:0.55:2 coground (Fig. 8g and e, respectively) clearly indicated an important role of citric acid in the disruption of VIN crystalline form. The Raman spectrum of the 1:1.1:2 composite sample, in which the changes with respect to pure VIN were more pronounced, was remarkably similar to that of Oxopocetin®, implying that VIN had the same form in both preparations.
From the aforementioned analyses it can be concluded the formation of a readily soluble amorphous solid, probably due to the formation of the amorphous citrate salt of VIN. To ascertain this point, additional investigations were conducted taking as a reference the commercial salt (Oxopocetine). In particular, X-ray photoelectron spectroscopy (XPS) and 15N cross-polarization magic angle spinning (CPMAS) SS NMR experiments, were selected because they are reported to be ideally suited for establishing the location of the proton in amorphous systems (36).
Figure 9 compares the N 1s XPS spectra (dots) of pure VIN (a), the polymer (b), the 1:1.1:2 coground system (c) and the VIN citrate commercial salt (Oxopocetine®) (d). Due to different charging shift observed in all the measured samples, the binding energy scale has been calibrated by fixing the C 1s photoemission line due to hydrocarbon to 284.6 eV (spectra not shown). The N 1s spectrum of pure VIN shows two components, corresponding to the two in-equivalent nitrogen atoms present on the molecule, N1 and N4 (Fig. 9a). The binding energies 400.3 eV and 398.9 eV are attributable to VIN N1 and N4, respectively. The N 1s XPS level of the polymer has an intermediate energy, and shows an intense and broad peak centered at 399.1 eV (Fig. 9b). Even though this peak was significantly broader than the others (1.8 eV vs 1.4), the data were reproduced by using only one component, because of sample in-homogeneity and disorder. The N 1s spectrum of the VIN citrate commercial salt (Oxopocetine®) (fig. 9c) showed two main peak components at 400.4 eV and 401.4 eV. The peak at lower binding energy corresponded, within the experimental error, to N1 atoms of pure VIN, and the highest binding energy peak to the N4 nitrogen atoms after protonation. Taking into account the previous results and the spectrum line-shape, the N 1s spectrum of the 1:1.1:2 coground system (fig. 9c) was reproduced using 3 peak components, which were found to be at 399.2 eV, 400.2 eV and 401.5 eV. The component at 399.2 eV corresponds to the polymer, while the component at 400.2 eV corresponds to N1 atoms. Finally, the peak at the highest binding energy (401.5 eV) was attributed to the N4 protonation by comparing this spectrum with that of Oxopocetine®. These results indicated the formation of VIN citrate by proton transfer through a solid state reaction conducted with the aid of the mechanical energy.
In the case of SS NMR, it is possible to evaluate the protonation state of amino and carboxylic groups either from their isotropic chemical shifts and from the chemical shift anisotropy (37). The 15N chemical shift is a useful parameter for the location of the hydrogen in hydrogen bonded systems involving nitrogen and oxygen atoms. Indeed, the 15N chemical shift is more sensitive to protonation or to the presence of hydrogen bonds than that of other nuclei such as 1H and 13C, due to its wider chemical shift range. Protonations as well as intermolecular hydrogen bonds produce high- or low-frequency shifts in the 15N values, according to the type of nitrogen atom and to the type of interaction (38).
Figure 10 shows the 15N CPMAS spectra of VIN, PVP-CL, Oxopocetine®, and of the coground sample.
The VIN spectrum was characterized by two resonances at 4.0 and 113.6 ppm for N4 and N1, respectively. Pyrrolidone nitrogen atoms of the polymer gave rise to a broad (width at half height = 480 Hz) signal around 104.6 ppm in agreement with the high heterogeneity of a polymeric system (Fig.10b). In the Oxopocetine® spectrum no significant variations were observed in the N1 chemical shift (111.3 ppm) with respect to that of VIN. On the other hand, the N4 resonance was shifted to 19.0 ppm clearly indicating a protonation of the group. The spectrum of the coground sample presented a broad signal (width at half height = 560 Hz) at about 108.7 ppm and a peak at 18.8 ppm. The former was attributed to the polymer nitrogen atoms with overlapped components around 144 ppm due to VIN N1 atoms. The latter was assigned to VIN N4 atoms indicating that in the coground sample the VIN molecules were protonated as well as in the Oxopocetine®.
Hence it can be concluded that the combination of the analytical techniques demonstrates the formation of the citrate salt of VIN in an amorphous solid form. This is in agreement to previous literature data (26) reporting that citric acid has the tendency to form amorphous structures.
Finally,  in vivo tests were carried out to ascertain the increased  bioavailability of VIN salt after oral administration to rats with respect its PM and to verify the bioequivalence with the commercial salt. In Fig. 11 the plasma concentration profiles are presented whilst the pharmacokinetic parameters are listed in Table III.  From these data, it is clear the great in vivo superiority of 1:1.1:2 coground system over its PM, being 4 folds more bioavailable. The bioequivalence in rats of the commercial salt and the salt prepared through mechanochemical process can be also deducted. The plasma profiles of the two salt samples are substantially super-imposable. 
The solid state in the selected coground sample (1:1.1:2 wt) was monitored by repeating the DSC and XRD analyses every 9 months for a period of 18 months (for brevity only the last sampling time was reported). These analyses testified the stability of the amorphous state of the salt during this period of time. 
The only difference on aging is the disappearing in the diffractogram (Fig.5 (i)) of the two signals originally at 26.3 and 32.4° of 2 , previously attributed to free (un-reacted) citric acid. Simultaneously,  in the DSC curves  (Fig. 6 (h)) a little peak appeared at about 60°C, compatible with the formation of  monohydrate citric acid during storage at ambient conditions. The monohydrate is, according to literature (34), the thermodynamically stable form in the temperature range below 34°C.

Conclusions 
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